Furthermore, given that existing myosin inhibitors are tailored for cardiac myosins, the development of inhibitors specifically targeting skeletal myosins presents opportunities for the treatment of skeletal myopathies caused by mutations exclusively in skeletal myosins. The gene discussed is MYH14; the disease is skeletal muscle disorder.